HBM-9027

N/A

Report date: 2024/07/11 17:46:13

Base Information

Drug NameHBM-9027
Drug Alias NameHBM-9027HBM9027
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockersTumor necrosis factor receptor superfamily member 5 agonistsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHarbour Biomed
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAnd Platinum Pharmaceutical(Shanghai) Co LtdHarbour Biomed
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A